Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: Is there a right or wrong way?

Farhad Ravandi

doi:10.1007/s11899-014-0204-7

Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: Is there a right or wrong way?

Farhad Ravandi

Leukemia

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Although combination chemotherapy regimens have been clearly successful in treating a proportion of patients with acute leukemia, we are probably close to a ceiling of maximal benefit from such combinations. Identification of targets in the cellular signaling pathways and development of specific drugs against them have added to our armamentarium; our current challenge is how to best incorporate these agents into the currently available regimens.

Original language	English (US)
Pages (from-to)	144-147
Number of pages	4
Journal	Current hematologic malignancy reports
Volume	9
Issue number	2
DOIs	https://doi.org/10.1007/s11899-014-0204-7
State	Published - Jun 2014

Keywords

Acute leukemia
Combination regimens
Monoclonal antibodies
Toxicity
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1007/s11899-014-0204-7

Cite this

@article{adb8604da6ce40c8972d43290e2968e6,

title = "Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: Is there a right or wrong way?",

abstract = "Although combination chemotherapy regimens have been clearly successful in treating a proportion of patients with acute leukemia, we are probably close to a ceiling of maximal benefit from such combinations. Identification of targets in the cellular signaling pathways and development of specific drugs against them have added to our armamentarium; our current challenge is how to best incorporate these agents into the currently available regimens.",

keywords = "Acute leukemia, Combination regimens, Monoclonal antibodies, Toxicity, Tyrosine kinase inhibitors",

author = "Farhad Ravandi",

year = "2014",

month = jun,

doi = "10.1007/s11899-014-0204-7",

language = "English (US)",

volume = "9",

pages = "144--147",

journal = "Current hematologic malignancy reports",

issn = "1558-8211",

publisher = "Springer Science + Business Media",

number = "2",

}

TY - JOUR

T1 - Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL

T2 - Is there a right or wrong way?

AU - Ravandi, Farhad

PY - 2014/6

Y1 - 2014/6

N2 - Although combination chemotherapy regimens have been clearly successful in treating a proportion of patients with acute leukemia, we are probably close to a ceiling of maximal benefit from such combinations. Identification of targets in the cellular signaling pathways and development of specific drugs against them have added to our armamentarium; our current challenge is how to best incorporate these agents into the currently available regimens.

AB - Although combination chemotherapy regimens have been clearly successful in treating a proportion of patients with acute leukemia, we are probably close to a ceiling of maximal benefit from such combinations. Identification of targets in the cellular signaling pathways and development of specific drugs against them have added to our armamentarium; our current challenge is how to best incorporate these agents into the currently available regimens.

KW - Acute leukemia

KW - Combination regimens

KW - Monoclonal antibodies

KW - Toxicity

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84903649356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903649356&partnerID=8YFLogxK

U2 - 10.1007/s11899-014-0204-7

DO - 10.1007/s11899-014-0204-7

M3 - Article

C2 - 24633744

AN - SCOPUS:84903649356

SN - 1558-8211

VL - 9

SP - 144

EP - 147

JO - Current hematologic malignancy reports

JF - Current hematologic malignancy reports

IS - 2

ER -

Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: Is there a right or wrong way?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this